Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas

Annals of Hematology
Jae-Cheol JoWon-Sik Lee

Abstract

Given the unsatisfactory survival in patients who received high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) for peripheral T-cell lymphomas (PTCLs), we conducted a prospective trial of busulfan (Bu), etoposide (E), cytarabine (A), and melphalan (M) (BuEAM), including IV Bu instead of carmustine (BCNU) as in standard BEAM, as a high-dose regimen in such patients. This study evaluated the efficacy and toxicity of BuEAM as a high-dose regimen for ASCT in patients with T-cell lymphomas. The high-dose chemotherapy at seven centers in Korea included Bu (3.2 mg/kg IV qd from day 6 to day 5), E (200 mg/m2 IV bid on day 4 and day 3), A (1 g/m2 IV qd on day 4 and day 3), and M (140 mg/m2 IV qd on day 2). Eighty-one patients were enrolled in this study. The main subtypes were peripheral T-cell lymphoma, not other specified (n = 32, 39.5%), NK/T-cell lymphoma (n = 22, 27.5%), and angioimmunoblastic T-cell lymphoma (n = 12, 14.8%). Upfront and salvage ASCTs were performed in 65 (80.2%) and 16 (19.8%) patients, respectively. The disease status of the patients before ASCT was 54 patients (66.7%) with complete response and 27 patients (33.3%) with partial response. The common grade-III toxicities were anorexia (8....Continue Reading

References

Mar 27, 2004·The New England Journal of Medicine·Noel MilpiedUNKNOWN Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang
Sep 16, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J RodriguezE Conde
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Feb 28, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S MercadalUNKNOWN Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB)
Mar 25, 2008·Therapeutics and Clinical Risk Management·D'Hondt LionelCanon Jean-Luc
Jul 16, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie VoseUNKNOWN International T-Cell Lymphoma Project
Nov 26, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter ReimerMartin Wilhelm
Jul 15, 2009·Bone Marrow Transplantation·A NumataUNKNOWN Fukuoka Blood and Marrow Transplantation Group
Aug 2, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francesco d'AmoreHelle E Toldbod
May 10, 2017·Current Hematologic Malignancy Reports·Umar ZahidFaiz Anwer
Dec 19, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G FossardE Bachy
Aug 15, 2019·Journal of Cancer Research and Clinical Oncology·Malte RoerdenWichard Vogel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.